



Xencor, Inc.  
Investor Relations Department  
111 West Lemon Avenue  
Monrovia, CA 91016  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

**NASDAQ: XNCR**


Last Trade:	21.96
Trade Time:	4:15 PM ET Jun 23, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	12.51 - 29.38
Volume	N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Since Xencor's founding in 1997, investors have been drawn to our remarkable scientific capabilities around monoclonal antibodies and solid intellectual property which serve as the engine behind our drug development programs. Currently, 11 candidates that have been engineered with Xencor's XmAb® technology are in clinical development by us or with partners. Xencor's internal programs include: XmAb®5871 in Phase 2 development for the treatment of IgG4-Related Disease, and also for the treatment of Systemic Lupus Erythematosus; XmAb®7195 in Phase 1a development fo... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Jun 16, 2017*

[Xencor Presents Interim Data from an Ongoing, Open-label, Phase 2 Study of XmAb®5871 in IgG4-Related Disease at EULAR 2017](#)

*Jun 8, 2017*

[Xencor Appoints Raphael Clynes, M.D., Ph.D., as Vice President of Translational Biology](#)

*May 30, 2017*

[Xencor to Present at Jefferies 2017 Global Healthcare Conference](#)

*May 11, 2017*

[Xencor's Lead Drug Candidate, XmAb5871, Receives Orphan Drug Designation from FDA for Treatment of IgG4-Related Disease](#)

*May 9, 2017*

[Xencor Reports First Quarter 2017 Financial Results](#)

## Financials [\[ View all \]](#)

[First Quarter Financial Results](#)

*Mar 1, 2017*

[Annual Report \(10-K\)](#)

*May 1, 2017*

[Proxy Statement \(DEF 14A\)](#)

*May 10, 2017*

[Quarterly Report \(10-Q\)](#)

*Nov 2, 2016*

[Quarterly Report \(10-Q\)](#)

*Aug 3, 2016*

[Quarterly Report \(10-Q\)](#)